Latest recommendation updates
ATAGI have published advice on the use of sedation for COVID-19 vaccination which provides a broad overview of the principles for the use of sedation as one of a range of measures to assist in the safe administration of COVID-19 vaccines.
Recent ATAGI considerations
On Wednesday 30 March 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 29 March 2022, over 56 million doses of COVID-19 vaccines have been administered in Australia.
ATAGI encourages parents of children aged 5-11 to make an appointment for the second dose of COVID-19 vaccine.
ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible. More information on COVID-19 boosters.
Ongoing ATAGI considerations
ATAGI is continuing to review all available and emerging evidence on the use of COVID-19 vaccines and treatments as part of its ongoing review of current recommendations.
ATAGI is also continuing to review evidence on the use of COVID-19 booster doses in adolescents aged 12-15 years, including data on serious illness, epidemiology and international use in this age group, including use in those with immuno-compromising conditions.
COVID-19 vaccine safety
The TGA Weekly Report provides a detailed breakdown of adverse events following immunisation.
Resources and recent statements
ATAGI recommends review of the following key resources:
- 6 April 2022: ATAGI advice on use of sedation for COVID-19 vaccination
- 25 March 2022: ATAGI recommendations on a winter booster dose of COVID-19 vaccine
- 2 March 2022: ATAGI updated advice on COVID-19 booster vaccinations
- 28 February 2022: ATAGI Clinical Guidance for COVID-19 vaccine providers
- 18 February 2022: ATAGI guidance on temporary medical exemptions for COVID‑19 vaccines
- 3 February 2022: ATAGI Statement on booster doses for adolescents aged 16 to 17 years
- 24 January 2022: ATAGI statement on the use of Novavax COVID-19 vaccine
- 19 January 2022: Updated ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised.